Revolution Medicines (RVMD) surges 37% on Phase 3 breakthrough: daraxonrasib nearly doubles median survival to 13.2 months vs. 6.7 months on chemo — hazard ratio 0.40, risk of death cut by 60%

NEW YORK, April 13, 2026. Revolution Medicines (Nasdaq: RVMD) surged approximately 37–39% on Monday after the Redwood City, California oncology company announced that daraxonrasib — its oral, once-daily multi-selective RAS(ON) inhibitor — had nearly doubled median overall survival versus standard chemotherapy in the pivotal global Phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma. According to the company’s GlobeNewswire press release, patients receiving daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months for chemotherapy — a hazard ratio of 0.40 with p < 0.0001, representing a 60% reduction in the risk of death. The trial met all primary and key secondary endpoints at the first interim analysis, with all PFS and OS endpoint results declared final. Progression-free survival was also statistically significantly improved. The stock hit a 52-week pre-market high of $147.33, opened the regular session at $132.26 from a prior close of $96.43, and held near $134–$136 at the close — a gain of approximately $38–40 per share in a single session. CNBC described the result as “almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy.”

Why this result is historically significant for pancreatic cancer

Pancreatic ductal adenocarcinoma is among the deadliest common cancers in existence. The American Cancer Society estimates approximately 50,000 Americans are diagnosed with pancreatic cancer annually, with a five-year survival rate hovering near 13% — the lowest of any major cancer type in the United States. The disease is characterised by late diagnosis, aggressive biology, and a near-total dependence on cytotoxic chemotherapy regimens that have barely changed in clinical standard of care since gemcitabine was approved in 1997. The second-line setting — patients whose disease has already progressed on prior therapy — is where the unmet need is most acute: median overall survival on second-line chemotherapy typically ranges from 5 to 8 months, with no targeted agent having previously demonstrated survival benefit in a Phase 3 setting for this population.

More than 90% of pancreatic cancers harbour activating mutations in RAS proteins — the highest RAS dependency of any major cancer type. That biological fact has made PDAC the most compelling target for RAS inhibitor development for decades, yet the structural complexity of mutant RAS proteins made them considered “undruggable” until the sotorasib and adagrasib approvals in KRAS G12C-mutant non-small cell lung cancer validated the target class between 2021 and 2022. The critical limitation of those approvals: KRAS G12C represents only a small minority of RAS mutations in pancreatic cancer — approximately 1–2% of PDAC cases. The vast majority of pancreatic RAS mutations are KRAS G12D, G12V, G12R, and other variants that first-generation selective inhibitors did not address. Daraxonrasib is the first investigational agent in a novel class designed to address the full, diverse spectrum of oncogenic RAS drivers as a multi-selective RAS(ON) inhibitor — binding multiple RAS variant proteins simultaneously rather than targeting a single mutation. RASolute 302 enrolled patients harbouring a wide range of RAS variants, including those with RAS G12 mutations and even patients without an identified RAS mutation (wild type) — a deliberate broad-population design that reflects the drug’s mechanism and substantially expands its potential commercial label if approved.

The trial design — what made RASolute 302 a registrational standard

RASolute 302 (NCT06625320) is an ongoing global, randomised, controlled Phase 3 registrational clinical trial. Patients were randomised to receive either an oral dose of 300 mg daraxonrasib once daily or investigator’s choice of standard of care cytotoxic chemotherapy — the same paclitaxel, gemcitabine, or FOLFIRINOX-based regimens that represent the current second-line standard of care. The trial enrolled previously treated patients with metastatic PDAC harbouring a broad range of RAS variants as well as RAS wild-type patients, making it one of the most inclusive pancreatic cancer registrational trials ever conducted. The primary endpoints were progression-free survival and overall survival in the RAS G12 mutation-positive subpopulation — the genotype most commonly seen in clinical practice — with the intent-to-treat population (all enrolled patients, including wild-type) assessed as a secondary endpoint. Both the primary and secondary survival outcomes favoured daraxonrasib with statistical significance at p < 0.0001. The company emphasised that the safety profile was manageable, with no new safety signals observed, and that daraxonrasib was “generally well tolerated” — an important qualification given that RAS pathway inhibitors have historically carried nausea and gastrointestinal toxicity concerns at therapeutically active doses. The oral once-daily administration — versus the intravenous delivery required for cytotoxic chemotherapy — is a clinically and commercially meaningful differentiator for patient quality of life throughout treatment.

What “first interim analysis declared final” means for the NDA timeline

One of the most clinically and strategically important details in Monday’s press release is the statement that all PFS and OS endpoint results are “considered final” based on the first interim analysis. This declaration matters enormously for the regulatory timeline. In most oncology Phase 3 trials, interim analyses are pre-specified statistical looks at accumulating data; if the data at an interim look are sufficiently compelling — typically requiring that the trial has crossed a pre-specified efficacy boundary — the Data Safety Monitoring Board can recommend stopping the trial early for benefit, and the sponsor can declare those results final rather than waiting for the planned final analysis. When RASolute 302’s results are declared final at the first interim, it means that the statistical evidence of benefit was so strong at that point that no further data collection is required to support a regulatory submission. The trial did not need to wait for additional patient follow-up. The DSMB determined, and the company concurred, that the data crossing the efficacy boundary at the first look — with p < 0.0001 for OS and a hazard ratio of 0.40 — represented a fully mature, definitive dataset. Revolution Medicines stated it intends to submit an NDA under a Commissioner’s National Priority Voucher — a designation that provides an accelerated review process measured in months rather than the standard 12-month review timeline. Combined with the possibility of a Breakthrough Therapy Designation designation (which the trial’s magnitude of benefit would strongly support, if not already held), the regulatory path to a potential commercial launch in second-line PDAC could be considerably shorter than a standard oncology NDA review cycle. An H2 2026 NDA submission — consistent with what Oppenheimer had previously anticipated — followed by a 2027 potential approval would make daraxonrasib a commercially available therapeutic within roughly 12 months of today’s announcement.

Analyst reaction — Oppenheimer to $165, BofA to $170, Jefferies $140

Oppenheimer analyst Jay Olson maintained an Outperform rating and raised his price target from $150 to $165 — the most visible post-trial upgrade heading into the session. Olson had previously been the most consistently bullish institutional voice on Revolution Medicines’ RAS(ON) platform, having flagged the potential for early Phase 3 stoppage and an H2 regulatory filing when the stock was trading near $93. BofA Securities raised its target to $170 with a Buy rating maintained — the most aggressive post-trial price target from a major institutional franchise. Jefferies, which had assumed coverage with a Buy and a $140 target earlier this year (raised from $88), signalled conviction that the first interim would succeed at the time of initiation — that conviction has now been validated. Combined, the analyst target range across the three most active institutional voices on the name is $140–$170, against a close near $134–$136. Even after the session’s 37–39% surge, the stock trades below the consensus of its most bullish institutional analysts — a dynamic that typically supports continued buying pressure from institutional managers benchmarking against those targets. CEO Mark Goldsmith characterised the results: “These results usher in a new era of RAS-targeted medicines for pancreatic cancer, which has been exclusively treated with cytotoxic intravenous chemotherapy.” A treating physician quoted in CNBC’s reporting called the results “truly transformational” for patients.

The $1 billion dual offering — dilution vs. commercial runway

Revolution Medicines has announced plans for a $1 billion dual offering — a combined equity and convertible notes offering designed to extend its capital runway through NDA prosecution, pre-commercial build-out, and early commercial infrastructure if daraxonrasib receives approval. The offering is a standard biotech capital market event in the context of a pivotal Phase 3 readout: with the stock 37% higher in a single session and analyst targets substantiating a durable valuation step-up, management has an unusually favourable opportunity to raise capital at prices materially above the pre-announcement trading range. The dilutive impact of an equity offering at $134–$136 — versus the $93 prices at which Oppenheimer’s prior Outperform note was written — is structurally manageable for existing shareholders. The convertible note component provides non-dilutive debt capital that can fund the commercial pre-launch period without additional share issuance, provided the stock maintains its post-trial price level. RVMD entered Monday with approximately $2.03 billion in cash and short-term investments, quarterly operating losses near $361.6 million, and R&D expenditure near $295 million per quarter — a burn rate that, without additional financing, would provide approximately five to six quarters of independent operational runway. The $1 billion offering, if completed at or near current prices, extends that runway through potential approval and into the early commercial phase, reducing dependence on partnership or acquisition for near-term survival. For investors new to reading biotech capital structure filings, PreMarket Daily’s SEC filings guide covers how to interpret offering prospectuses alongside an 8-K trial readout.

The broader RAS(ON) platform — RASolute 303, zoldonrasib, and AACR 2026

Monday’s RASolute 302 readout is analytically significant beyond daraxonrasib’s second-line PDAC indication because it validates Revolution Medicines’ entire RAS(ON) platform thesis — the hypothesis that multi-selective RAS(ON) inhibition, targeting the GTP-bound active state of RAS proteins across multiple variants simultaneously, is the mechanism-of-action approach capable of addressing the full spectrum of RAS-addicted cancers. According to Invezz, the company is simultaneously advancing four active registrational trials across pancreatic and non-small cell lung cancer: RASolute 302 (now complete for its primary endpoint), RASolute 303 (first-line mPDAC, all RAS genotypes), and two additional trials in NSCLC. The RASolute 303 design — testing daraxonrasib as monotherapy and in combination with chemotherapy in first-line metastatic PDAC across all RAS genotypes — is the company’s bid for the primary treatment setting, which dwarfs the second-line population in commercial scale. If daraxonrasib demonstrates efficacy in first-line PDAC, the addressable patient population is essentially the full pancreatic cancer incidence — approximately 50,000 new US diagnoses annually.

Zoldonrasib — Revolution Medicines’ KRAS G12D-selective inhibitor — targets the single most common mutation in PDAC (approximately 40% of cases) with a more precise mechanism than daraxonrasib’s multi-selective approach. Nine data presentations are planned for the 2026 American Association for Cancer Research annual meeting, covering daraxonrasib, zoldonrasib in KRAS G12D NSCLC, multiple Phase 1/2 daraxonrasib data sets in first-line pancreatic cancer, a Phase 3 NSCLC design versus docetaxel, and preclinical next-generation RAS(ON) work. That AACR catalyst calendar — now landing against the backdrop of a validated Phase 3 daraxonrasib dataset — positions RVMD as one of the most catalyst-dense oncology names on the market in the near term. The competitive landscape in RAS oncology has bifurcated: first-generation KRAS G12C-selective inhibitors (Amgen’s sotorasib/Lumakras; Mirati’s adagrasib/Krazati) target a small minority of pancreatic cases and have not demonstrated Phase 3 survival benefits in PDAC specifically. Revolution Medicines’ multi-selective approach — validated today by a hazard ratio of 0.40 across the full breadth of RAS mutations in a PDAC population — represents a category-defining clinical result that no competitor has matched in this indication. Healthcare is one of the ten major S&P 500 sectors; biotech data events of this magnitude typically generate significant sector rotation and sympathy moves in oncology-adjacent names on the session.

Risks — insider sales, valuation, and what a 37% gap leaves behind

The investment case at $134–$136 is materially different from the investment case at $96 forty-eight hours ago, and several risk factors warrant explicit acknowledgment. SEC Form 4 filings show CEO Mark Goldsmith sold approximately $1.28 million worth of shares in March 2026, while President of R&D Stephen Kelsey, COO Margaret Horn, and Chief Global Commercialization Officer Anthony Mancini each filed six- to seven-figure sales during the same period — though all retained sizable positions. Insider sales ahead of a pivotal binary readout are common in biotech and do not automatically signal adverse knowledge, but the Form 4 pattern is a relevant data point for risk-aware investors. The stock’s valuation at $134–$136 reflects near-consensus of a successful NDA submission and eventual commercial approval — any regulatory setback, manufacturing scale-up challenge, payer access headwind, or clinical complication in post-marketing commitments would be priced against a significantly higher starting point than existed before today. The $1 billion dual offering, if priced near current levels, also introduces near-term dilution that will be quantifiable when terms are announced. The intraday trading profile — pre-market high of $147.33, dip to $127 in the regular session, recovery to $136.80, close near $134–$136 — is consistent with some institutional profit-taking against heavy retail and momentum buying. That price discovery dynamic typically produces continued consolidation in the days immediately following a gap-up event of this magnitude, with the breakout zone of $95–$105 representing the technical support level that disciplined swing traders would reference if the stock gives back a portion of the day’s gains in subsequent sessions. Understanding how pre-market gap-ups behave in the regular session is directly relevant to positioning in the days following a result of this type.